Healthy.io’s Smartphone Diagnostics Are Quietly Redefining Preventive Healthcare

The most transformative innovations in healthcare rarely arrive with noise, they arrive with utility.

In a world still obsessed with high-cost hospital infrastructure and complex diagnostics, Healthy.io has quietly done something extraordinary: it has turned the smartphone, a device most people already own, into a certified clinical diagnostic tool.

Founded by Yonatan Adiri in 2013, Healthy.io built two flagship products: Dip.io (a smartphone-based urinalysis for multiple parameters) and Minuteful Kidney (an at-home albumin-to-creatinine ratio, or ACR, test for early chronic kidney disease). Using computer vision and AI, the platform calibrates for camera, lighting, and strip variability to deliver lab-grade accuracy from home in minutes. Peer-reviewed studies and real-world pilots with the UK’s NHS and U.S. health systems have demonstrated clinical concordance with standard laboratory methods, particularly for ACR screening in diabetes and hypertension populations.

The company’s journey began with a simple question: if high-quality cameras are ubiquitous, why should basic diagnostics still require a lab visit?

That insight led to CE marking in the EU and FDA 510(k) clearance in the U.S. for specific use cases, including the Minuteful Kidney home ACR test. In England, large-scale NHS initiatives have mailed home test kits to at-risk patients, driving materially higher screening rates among those who historically miss annual checks.

The need is acute. An estimated 1 in 7 adults in the U.S. has CKD, and up to 9 in 10 are unaware. Early detection hinges on simple ACR testing, yet adherence is persistently low due to logistics and access frictions. Healthy.io’s at-home model collapses those barriers, converting non-completers into screened patients and catching kidney decline earlier, when interventions are cheaper and more effective.

Commercial traction has followed the outcomes. Healthy.io has raised over $200 million across rounds from leading digital health investors, secured enterprise contracts with payers and providers, and scaled distribution through pharmacy and health plan partnerships. The company’s business case is anchored in quality incentives and total cost-of-care reduction: better screening closes care gaps, improves HEDIS and Star ratings, and averts costly late-stage kidney complications.

Against industry benchmarks, Healthy.io competes as a category leader in computer-vision urinalysis. While point-of-care devices and mail-in labs remain alternatives, smartphone-native diagnostics offer unmatched reach and engagement. The company positions itself where preventive care meets consumer-grade usability, on the patient’s terms.

Growth catalysts ahead include payer mandates for CKD screening in high-risk cohorts, expansion into UTI and pregnancy-related urinalysis pathways, and broader European reimbursement. Expect steady double-digit annual growth as home-based testing becomes the default for chronic disease monitoring, turning the smartphone into the front door of preventive care.

Note: Regulatory clearances, product names (Dip.io, Minuteful Kidney), and NHS collaborations are based on publicly reported information through 2024–2025.